Myotonic Dystrophy in Czech Republic: Data from the National
Transkript
Myotonic Dystrophy in Czech Republic: Data from the National Registry Stanislav Voháňkaa,b, Olesja Parmováa , Radim Mazanecc, Jana Strenkovád, Petr Ridzoňe, Edvard Ehlerf, Alexandr Vávraf, Martin Forgáčg, Jana Junkerováh, Tomáš Božovskýi, Pavel Kuncj aUniversity Hospital and Medical Faculty Masaryk University Brno, bCentral European Institute of Technology, CEITEC MU, Masaryk University, Brno, cUniversity Hospital Prague- Motol and Medical Faculty Charles University, Prague, dInstitute of Biostatistics and Analyses, Masaryk University, Brno, eThomayer Hospital Prague, fRegional Hospital Pardubice, Faculty of Health Care Studies, University Pardubice, gGeneral University Hospital and Medical Faculty Charles University, Prague, hUniversity Hospital Ostrava, iUniversity Hospital Pilsen, jUniversity Hospital Hradec Králové Background and objectives. Myotonic dystrophy is the most common form of muscular dystrophy that begins predominantly in adulthood. The prevalence of the two types varies among different geographic and ethnic populations. Patient registries represent key instruments by pooling data for clinical research, epidemiological assessment, and observational studies in rare diseases. Patients and Methods. The Czech National Registry of Myotonic Disorders was established in 2011 and up to August 2015 393 patients from 8 centres have been included. Technological remarks The technological aspect of the project, the data collection, storage and backup and their analysis are provided by the Institute of Biostatistics and Analyses, Masaryk University, Brno, CR. On-line data collection is based on a TRIALDB system developed on Yale University, Connecticut, USA, which is widely used for this purpose. So it is not necessary to install any additional computer software. The database can be accessed only by authorized persons using their login and password. For each patient is generated a unique ID; all data transfer is encrypted and the system is designed to prevent their unauthorized use during data transfer. Laws and regulations in CR require having an informed consent from all patients whose data are used in the registry. All claims for personal data protection were met. Data are stored on the central server on Masaryk University in Brno in Oracle 9i database. Other (user-friendly) functions Total (N=348) • Database users are allowed to print the submitted patient forms Descriptive statistics • Selected data are on-line exported to the web pages of the ReaDy (ready.registry.cz) Myotonic dystrophy - age of onset (N=265) Motor function (N=330) Ambulatory - unassisted Ambulatory - assisted Non -ambulatory Able to walk (N=329) Wheelchair use (N=330) Full -time Part -time No 6 -minute walk test (m) (N=140) Myotonia (N=316) None Mild Severe MRC (N=182) Heart condition (N=299) Arrhythmia Cardiomyopathy Yes , no further specified No Unknown A ge – heart condition (N=49) PR interval (N=101) QRS interval (N=99) ECG (N=275) Dysphagia (N=305) FVC (N=161) Creatine kinase (N=264) - continuous Normal (men? 2.9; women? 2 .3) Abnormal Myoglobin (N=237) - continuous Normal (men ? 72 ; women ? 58) Abnorm al Cataract (N=321) Fatigue (N=313) None Mild Severe FUP (month) (N=231) • Each patients can see her/his own data after secure individual authentication • The battery of questionnaires are available, partially for self-evaluation of patients • Documents repository for patients and physicians • Helpdesk DM1 vs. DM2 1 2 DM1 (N=141) 35.0 (12.0 -60.0) 25.0 (10.0 299 (90.6%) 27 (8.2%) 4 (1.2%) 315 (95.7%) DM2 (N=207) -54.0) 119 (90.2%) 10 (7.6%) 3 (2.3%) 122 (93.1%) 40.0 (17.0 p -62.0) <0.001 180 (90.9%) 17 (8.6%) 1 (0.5%) 193 (97.4%) 0.410 DM1 vs. DM2 0.091 4 (1.2%) 5 (1.5%) 321 (97.3%) 400.5 (100.0 -720.0) 3 (2.3%) 3 (2.3%) 126 (95.5%) 400.0 (90.0 -800.0) 1 (0.5%) 2 (1%) 195 (98.5%) 425.0 (100.0 -700.0) 89 (28.2%) 170 (53.8%) 57 (18%) 155.0 (106.8 -170.0) 16 (12.7%) 66 (52.4%) 44 (34.9%) 150.8 (101.8 -170.0) 73 (38.4%) 104 (54.7%) 13 (6.8%) 157.3 (106.8 -170.0) 0.280 DM1 age of onset (y) 0.108 60 max 54 <0.001 50 0.032 40 34 (11.4%) 8 (2.7%) 22 (7.4%) 189 (63.2%) 46 (15.4%) 45.0 (20.0 -71.0) 158.0 (0.2 -200.0) 80.0 (0.1 -160.0) 156 (52.4%) 36 (11.8%) 89.0 (32.0 -114.0) 3.9 (1.3 -17.7) 55 (20.8%) 209 (79.2%) 84.8 (31.0 -235.3) 62 (26.2%) 175 (73.8%) 95 (29.6%) 22 (18.8%) 4 (3.4%) 12 (10.3%) 58 (49.6%) 21 (17.9%) 40.5 (20.0 -57.0) 155.0 (0.2 -236.0) 80.0 (0.1 -170.0) 65 (60.2%) 22 (18.5%) 79.0 (29.0 -103.0) 3.6 (1.1 -11.9) 24 (24.5%) 74 (75.5%) 93.1 (37.2 -249.4) 16 (18.4%) 71 (81.6%) 32 (25.4%) 12 (6.6%) 4 (2.2%) 10 (5.5%) 131 (72%) 25 (13.7%) 55.0 (13.0 -2 012.0) 158.0 (0.2 -200.0) 80.0 (0.1 - 120.0) 79 (47.3%) 14 (7.5%) 92.8 (55.0 -123.0) 4.0 (1.3 -20.1) 31 (18.7%) 135 (81.3%) 79.8 (31.0 -229.7) 46 (30.7%) 104 (69.3%) 63 (32.3%) 148 (47.3%) 138 (44.1%) 27 (8.6%) 16.0 (0.0 -121.0) 40 (32.8%) 64 (52.5%) 18 (14.8%) 19.5 (0.0 -162.0) 108 (56.5%) 74 (38.7%) 9 (4.7%) 16.0 (0.0 - 101.0) 30 0.001 mean 25 20 10 0.001 0.967 0.719 0.126 <0.001 <0.001 0.344 DM2 age of onset (y) 0.275 70 0.185 60 0.046 min 4 0 max 62 50 0.388 mean 40 40 th described by absolute and relative frequencies for categorical and median (5 - 95 Fisher exact test for categorical and Mann - Whitney U test for continuous variables th <0.001 0.155 perc.) for continuous variables 30 min 17 20 10 0 Myotonia (DM1, DM2) Results 236 (60%) patients are suffering from myotonic dystrophy type 2 (DM2) and 157 (40%) from myotonic dystrophy type 1 (DM1), 248 females (63%) and 145 males (37%). Mean age in the time of the registry entering is 45 years, approximately 10 years after disease manifestation which was in patient with DM1 25 (10- 54) years and in persons with DM2 40 (17-62) years. Nearly all patients with both forms are ambulatory (assisted or unassisted). Only 4 patients are wheelchair bound (three with DM1). We could not found the difference between both types in 6 min. walking test and motor functions expressed as summary of MRC score. The presence of cataracts was also similar in both groups. Patients suffering from MD1 have had more severe myotonia, heart problems (esp. arrhythmias), dysphagia, and fatigue (p<0.001, Fisher exact test for categorical and Mann-Whitney U test for continuous variables). The mean follow-up time in the registry is 16 months. (Some pictures and data are based on the last update August 31, 2015) None 60% 50% 40% 30% 20% 10% 0% Severe Mild DM1 DM2 Walking ability (DM1, DM2) 100% 90% 80% 70% 60% 50% 40% Annual recruitment rate Recruitment rate since launching Contributions of the neuromuscular centres 30% 20% 10% 0% Brno Ambulatory ‐ unassisted Ambulatory ‐ assisted Non‐ambulatory Prague Motol Prague Thomayer Age at onset (DM1, DM2) Ostrava Prague General Pardubice Pilsen Hradec Kralove 0 20 40 60 80 100 120 140 160 180 Conclusion In Czech population (Middle Europe, 10.5 mil. inhabitants) is more frequent DM2 than DM1 Patients with DM1 are younger and more compromised than patients with DM2 DM2 is the most frequent muscular dystrophy among adult patients in Czech Republic Acknowledgement The registry is the common work of all Czech neuromuscular centres, molecular biology laboratories (Centre of Molecular Biology and Gene Therapy, University Hospital Brno and Institute of Biology and Medical Genetics Prague-Motol), and Institute of Biostatistics and Analyses (Masaryk University Brno). References 1) Brabec P, Vondráček P, Klimes D, Baumeister S, Lochmüller H, Pavlík T, et al. Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscul. Disord. 2009; 19: 250–254. 2) Sárközy A, Bushby K, Béroud C, Lochmüller H. 157th ENMC International Workshop: patient registries for rare, inherited muscular disorders 25-27 January 2008 Naarden, The Netherlands. Neuromuscul. Disord. 2008; 18: 997–1001. 3) Thompson R, Schoser B, Monckton DG, Blonsky K, Lochmüller H. Patient Registries and Trial Readiness in Myotonic Dystrophy--TREAT-NMD/Marigold International Workshop Report. Neuromuscul. Disord. 2009; 19: 860–866. Stanislav Voháňka, Neuromuscular Centre, Department of Neurology, University Hospital Brno [email protected], www.fnbrno.cz, www. neuromuskularni-sekce.cz www.ready.registry.cz
Podobné dokumenty
Otevřít v novém okně
Soutěž Evropský strom roku vznikla v roce 2011 v návaznosti na oblíbenou anketu Strom roku, kterou v České republice dlouhodobě pořádá
Nadace Partnerství. Smyslem ankety je poukázat na zajímavé sta...
Prognostické faktory myastenie Kdy selhává terapie?
– Rozvoj trvalé slabosti faryngeálního a
faciálního svalstva včetně atrofie
– Většinou se nedosáhne kompletní remise
– Nutnost intenzivnější IS terapie
Diagnostika a péče u Duchennovy svalové dystrofie
pro svalovou dystrofii („Muscular Dystrophy Association“) a Parent Project Muscular Dystrophy. Ve Spojených státech amerických se výzkumné a zdravotnické
iniciativy zaměřily na problematiku svalové...
Dotazník pro nemocné s kanálopatiemi
Syndromy: Dominantní
Draslíkem agravovaná myotonie (Potassium-aggravated myotonia-PAM)
o Myotonia fluctuans
o Myotonia permanens
o Acetazolamid responzivní myotonie
o Častější než PAM způsobená mut...
Číslo 23 - Genetická společnost Gregora Mendela
Speciálně je tento výzkum zaměřen na soubor morfologických recesivních mutantů a soubor
embryonálně letálních T -DNA mutantů, a dále na mutace podmiňující pozdní kvetení.
Dlouhodobě je monitorován ...
Zpravodaj AMD 2015/1 - Asociace muskulárních dystrofiků v ČR
Tel.: 272 933 777, mimo tyto hodiny pak na tel.: 722 946 323 – Iveta Jelínková
Se svými dotazy se můžete obracet i písemně na adresu kanceláře:
AMD v ČR, Petýrkova 1953, 148 00 PRAHA 4 – Chodov neb...